Valeant Pitches Potential Eye Drug, Research Focus

Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan. [...] Valeant Chairman and CEO Michael Pearson said Thursday that his company is committed to health care innovation and funding important research. Valeant said the potential glaucoma drug, Vesneo, lowered eye pressure in late-stage research on patients with glaucoma or ocular hypertension.

Sections:  news   business   
BING NEWS:
  • Viridian shares soar after latest trial success for thyroid eye disease drug
    Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...
    12/16/2024 - 1:00 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News